多西他赛联合顺铂同步放疗治疗晚期食管癌患者的疗效及安全性  

Efficacy and safety of docetaxel combined with cisplatin and concurrent radiotherapy in the treatment of advanced esophageal cancer

作　　者：华玲 杨婷芳 陈贤峰 严冬梅 王敏 HUA Ling;YANG Tingfang;CHEN Xianfeng;YAN Dongmei;WANG Min(Department of Pharmacy,Shanghai Jinshan District Tinglin Hospital,Shanghai 201505,China)

机构地区：[1]上海市金山区亭林医院药剂科,上海201505

出　　处：《癌症进展》2023年第13期1431-1433,1470,共4页Oncology Progress

基　　金：金山区科学技术创新资金项目(2021-3-23)。

摘　　要：目的 探讨多西他赛联合顺铂同步放疗治疗晚期食管癌患者的疗效及安全性。方法 根据治疗方式的不同将90例晚期食管癌患者分为对照组(n=47)和观察组(n=43),两组患者均实施三维适形调强放疗,对照组患者予以顺铂联合氟尿嘧啶化疗,观察组患者予以多西他赛联合顺铂化疗。比较两组患者的临床疗效、肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、神经元特异性烯醇化酶(NSE)]水平、不良反应发生情况及生存情况。结果 观察组患者的总有效率高于对照组,差异有统计学意义(P﹤0.05)。治疗后,两组患者的血清CEA、CA125、NSE水平均低于本组治疗前,观察组患者的血清CEA、CA125、NSE水平均低于对照组,差异均有统计学意义(P﹤0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。观察组患者的1、2年生存率均高于对照组,差异均有统计学意义(P﹤0.05)。结论 多西他赛联合顺铂同步放疗治疗晚期食管癌患者可提高临床疗效和生存率,且不增加不良反应。Objective To explore the efficacy and safety of docetaxel combined with cisplatin and concurrent radiotherapy in the treatment of advanced esophageal cancer.Method A total of 90 patients with advanced esophageal cancer were divided into control group(n=47)and observation group(n=43)according to different treatment methods.Patients in both groups received three-dimensional conformal intensity modulated radiotherapy,the patients in the control group were received cisplatin+fluorouracil chemotherapy,and patients in the observation group were received docetaxel+cisplatin chemotherapy.The clinical efficacy,tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and neuron specific enolase(NSE)],adverse reactions and survival of the two groups were compared.Result The total effective rate of the observation group was higher than that of the control group(P<0.05).After treatment,the serum CEA,CA125 and NSE levels in both groups were decreased,with lower levels in the observation group than those in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).The 1-year and 2-year survival rates of the observation group were higher than those of the control group(P<0.05).Conclusion Docetaxel combined with cisplatin and concurrent radiotherapy in the treatment of advanced esophageal cancer can improve the clinical efficacy and survival rate of patients without increasing adverse reactions.

关 键 词：食管癌 同步放疗 多西他赛 顺铂 

分 类 号：R735.1[医药卫生—肿瘤]